APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032

Report ID 17397430022 January 2026209 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cancer Immunotherapy Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Immunotherapy Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Immunotherapy Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Immunotherapy Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Immunotherapy Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Immunotherapy Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cancer Immunotherapy Drugs sales, projected growth trends, production technology, application and end-user industry.

Cancer Immunotherapy Drugs Segment by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GSK

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Hengrui Medicine

Gilead Sciences

Exelixis

Bristol-Myers Squibb

Cancer Immunotherapy Drugs Segment by Type

CAR-T Cell Therapy

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Cancer Immunotherapy Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Cancer Immunotherapy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cancer Immunotherapy Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Immunotherapy Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CAR-T Cell Therapy Major Manufacturers Table 3. Cytokine-Based Immunotherapy Major Manufacturers Table 4. Immune Checkpoint Inhibitors Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Blood-related Cancer Major Manufacturers Table 8. Breast Cancer Major Manufacturers Table 9. Prostate Cancer Major Manufacturers Table 10. Lung Cancer Major Manufacturers Table 11. Other Major Manufacturers Table 12. Cancer Immunotherapy Drugs Industry Trends Table 13. Cancer Immunotherapy Drugs Industry Drivers Table 14. Cancer Immunotherapy Drugs Industry Opportunities and Challenges Table 15. Cancer Immunotherapy Drugs Industry Restraints Table 16. Global Cancer Immunotherapy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2026) Table 20. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2027-2032) Table 21. Global Cancer Immunotherapy Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units) Table 23. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (K Units) Table 24. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2026) Table 25. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2027-2032) Table 26. Global Cancer Immunotherapy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Cancer Immunotherapy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Cancer Immunotherapy Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Cancer Immunotherapy Drugs Sales Market Share by Manufacturers (2021-2026) Table 30. Global Cancer Immunotherapy Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Cancer Immunotherapy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Cancer Immunotherapy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Cancer Immunotherapy Drugs Manufacturers, Product Type & Application Table 34. Global Cancer Immunotherapy Drugs Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Cancer Immunotherapy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Cancer Immunotherapy Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2026) Table 41. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2027-2032) Table 42. Global Cancer Immunotherapy Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 44. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 45. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2026) Table 46. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2027-2032) Table 47. Global Cancer Immunotherapy Drugs Price by Type (2021-2026) & (US$/Unit) Table 48. Global Cancer Immunotherapy Drugs Price by Type (2027-2032) & (US$/Unit) Table 49. Global Cancer Immunotherapy Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2026) Table 53. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2027-2032) Table 54. Global Cancer Immunotherapy Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 56. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2026) Table 58. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2027-2032) Table 59. Global Cancer Immunotherapy Drugs Price by Application (2021-2026) & (US$/Unit) Table 60. Global Cancer Immunotherapy Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. Takeda Company Information Table 62. Takeda Business Overview Table 63. Takeda Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Takeda Cancer Immunotherapy Drugs Product Portfolio Table 65. Takeda Recent Development Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Novartis Cancer Immunotherapy Drugs Product Portfolio Table 75. Novartis Recent Development Table 76. Merck KGaA Company Information Table 77. Merck KGaA Business Overview Table 78. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio Table 80. Merck KGaA Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Roche Cancer Immunotherapy Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Eli Lilly Company Information Table 87. Eli Lilly Business Overview Table 88. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio Table 90. Eli Lilly Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Pfizer Cancer Immunotherapy Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. GSK Company Information Table 97. GSK Business Overview Table 98. GSK Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. GSK Cancer Immunotherapy Drugs Product Portfolio Table 100. GSK Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Amgen Cancer Immunotherapy Drugs Product Portfolio Table 105. Amgen Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. AbbVie Cancer Immunotherapy Drugs Product Portfolio Table 110. AbbVie Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Seagen Company Information Table 117. Seagen Business Overview Table 118. Seagen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Seagen Cancer Immunotherapy Drugs Product Portfolio Table 120. Seagen Recent Development Table 121. Regeneron Company Information Table 122. Regeneron Business Overview Table 123. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Regeneron Cancer Immunotherapy Drugs Product Portfolio Table 125. Regeneron Recent Development Table 126. Ono Pharmaceutical Company Information Table 127. Ono Pharmaceutical Business Overview Table 128. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio Table 130. Ono Pharmaceutical Recent Development Table 131. Merck & Co Company Information Table 132. Merck & Co Business Overview Table 133. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Merck & Co Cancer Immunotherapy Drugs Product Portfolio Table 135. Merck & Co Recent Development Table 136. Innovent Company Information Table 137. Innovent Business Overview Table 138. Innovent Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Innovent Cancer Immunotherapy Drugs Product Portfolio Table 140. Innovent Recent Development Table 141. Hengrui Medicine Company Information Table 142. Hengrui Medicine Business Overview Table 143. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio Table 145. Hengrui Medicine Recent Development Table 146. Gilead Sciences Company Information Table 147. Gilead Sciences Business Overview Table 148. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio Table 150. Gilead Sciences Recent Development Table 151. Exelixis Company Information Table 152. Exelixis Business Overview Table 153. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Exelixis Cancer Immunotherapy Drugs Product Portfolio Table 155. Exelixis Recent Development Table 156. Bristol-Myers Squibb Company Information Table 157. Bristol-Myers Squibb Business Overview Table 158. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio Table 160. Bristol-Myers Squibb Recent Development Table 161. North America Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 162. North America Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 163. North America Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 164. North America Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 165. North America Cancer Immunotherapy Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 166. North America Cancer Immunotherapy Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 167. North America Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 168. North America Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 169. North America Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 170. North America Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 171. North America Cancer Immunotherapy Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 172. North America Cancer Immunotherapy Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 173. North America Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. North America Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. North America Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. North America Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. North America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 178. North America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 179. North America Cancer Immunotherapy Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 180. North America Cancer Immunotherapy Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 181. United States Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 182. Canada Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 183. Europe Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 184. Europe Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 185. Europe Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 186. Europe Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 187. Europe Cancer Immunotherapy Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 188. Europe Cancer Immunotherapy Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 189. Europe Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 190. Europe Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 191. Europe Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 192. Europe Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 193. Europe Cancer Immunotherapy Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 194. Europe Cancer Immunotherapy Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 195. Europe Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. Europe Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 197. Europe Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 198. Europe Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 199. Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 200. Europe Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 201. Europe Cancer Immunotherapy Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 202. Europe Cancer Immunotherapy Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 203. Germany Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 204. France Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 205. U.K. Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 206. Italy Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 207. Netherlands Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 208. Nordic Countries Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 209. China Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 210. China Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 211. China Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 212. China Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 213. China Cancer Immunotherapy Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 214. China Cancer Immunotherapy Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 215. China Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 216. China Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 217. China Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 218. China Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 219. China Cancer Immunotherapy Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 220. China Cancer Immunotherapy Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Asia Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 222. Asia Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 223. Asia Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 224. Asia Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 225. Asia Cancer Immunotherapy Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 226. Asia Cancer Immunotherapy Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 227. Asia Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 228. Asia Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 229. Asia Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 230. Asia Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 231. Asia Cancer Immunotherapy Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 232. Asia Cancer Immunotherapy Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 233. Asia Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. Asia Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. Asia Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. Asia Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 237. Asia Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 238. Asia Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 239. Asia Cancer Immunotherapy Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 240. Asia Cancer Immunotherapy Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Japan Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 242. South Korea Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 243. India Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 244. Australia Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 245. China Taiwan Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 246. Southeast Asia Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 247. SAMEA Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 248. SAMEA Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 249. SAMEA Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 250. SAMEA Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 251. SAMEA Cancer Immunotherapy Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 252. SAMEA Cancer Immunotherapy Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 253. SAMEA Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 254. SAMEA Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 255. SAMEA Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 256. SAMEA Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 257. SAMEA Cancer Immunotherapy Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 258. SAMEA Cancer Immunotherapy Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 259. SAMEA Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 260. SAMEA Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 261. SAMEA Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 262. SAMEA Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 263. SAMEA Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 264. SAMEA Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 265. SAMEA Cancer Immunotherapy Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 266. SAMEA Cancer Immunotherapy Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 267. Brazil Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 268. Argentina Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 269. Chile Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 270. Colombia Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 271. Peru Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 272. Saudi Arabia Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 273. Israel Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 274. UAE Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 275. Turkey Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 276. Iran Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 277. Egypt Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Table 278. Key Raw Materials Table 279. Raw Materials Key Suppliers Table 280. Cancer Immunotherapy Drugs Distributors List Table 281. Cancer Immunotherapy Drugs Customers List Table 282. Research Programs/Design for This Report Table 283. Authors List of This Report Table 284. Secondary Sources Table 285. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drugs Image Figure 2. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. CAR-T Cell Therapy Image Figure 5. Cytokine-Based Immunotherapy Image Figure 6. Immune Checkpoint Inhibitors Image Figure 7. Other Image Figure 8. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Cancer Immunotherapy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Blood-related Cancer Image Figure 11. Breast Cancer Image Figure 12. Prostate Cancer Image Figure 13. Lung Cancer Image Figure 14. Other Image Figure 15. Global Cancer Immunotherapy Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Figure 17. Global Cancer Immunotherapy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Cancer Immunotherapy Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2032) Figure 20. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units) Figure 21. Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Cancer Immunotherapy Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Europe Cancer Immunotherapy Drugs Sales YoY (2021-2032) & (K Units) Figure 25. China Cancer Immunotherapy Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Cancer Immunotherapy Drugs Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales YoY (2021-2032) & (K Units) Figure 28. Global Cancer Immunotherapy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Cancer Immunotherapy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Cancer Immunotherapy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Cancer Immunotherapy Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032) Figure 34. Global Cancer Immunotherapy Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Cancer Immunotherapy Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032) Figure 37. Global Cancer Immunotherapy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Cancer Immunotherapy Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032) Figure 40. Global Cancer Immunotherapy Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Cancer Immunotherapy Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032) Figure 43. North America Cancer Immunotherapy Drugs Revenue Share by Type (2021-2032) Figure 44. North America Cancer Immunotherapy Drugs Sales Share by Type (2021-2032) Figure 45. North America Cancer Immunotherapy Drugs Revenue Share by Application (2021-2032) Figure 46. North America Cancer Immunotherapy Drugs Sales Share by Application (2021-2032) Figure 47. North America Cancer Immunotherapy Drugs Revenue Share by Country (2021-2032) Figure 48. North America Cancer Immunotherapy Drugs Sales Share by Country (2021-2032) Figure 49. Europe Cancer Immunotherapy Drugs Revenue Share by Type (2021-2032) Figure 50. Europe Cancer Immunotherapy Drugs Sales Share by Type (2021-2032) Figure 51. Europe Cancer Immunotherapy Drugs Revenue Share by Application (2021-2032) Figure 52. Europe Cancer Immunotherapy Drugs Sales Share by Application (2021-2032) Figure 53. Europe Cancer Immunotherapy Drugs Revenue Share by Country (2021-2032) Figure 54. Europe Cancer Immunotherapy Drugs Sales Share by Country (2021-2032) Figure 55. China Cancer Immunotherapy Drugs Revenue Share by Type (2021-2032) Figure 56. China Cancer Immunotherapy Drugs Sales Share by Type (2021-2032) Figure 57. China Cancer Immunotherapy Drugs Revenue Share by Application (2021-2032) Figure 58. China Cancer Immunotherapy Drugs Sales Share by Application (2021-2032) Figure 59. Asia Cancer Immunotherapy Drugs Revenue Share by Type (2021-2032) Figure 60. Asia Cancer Immunotherapy Drugs Sales Share by Type (2021-2032) Figure 61. Asia Cancer Immunotherapy Drugs Revenue Share by Application (2021-2032) Figure 62. Asia Cancer Immunotherapy Drugs Sales Share by Application (2021-2032) Figure 63. Asia Cancer Immunotherapy Drugs Revenue Share by Country (2021-2032) Figure 64. Asia Cancer Immunotherapy Drugs Sales Share by Country (2021-2032) Figure 65. SAMEA Cancer Immunotherapy Drugs Revenue Share by Type (2021-2032) Figure 66. SAMEA Cancer Immunotherapy Drugs Sales Share by Type (2021-2032) Figure 67. SAMEA Cancer Immunotherapy Drugs Revenue Share by Application (2021-2032) Figure 68. SAMEA Cancer Immunotherapy Drugs Sales Share by Application (2021-2032) Figure 69. SAMEA Cancer Immunotherapy Drugs Revenue Share by Country (2021-2032) Figure 70. SAMEA Cancer Immunotherapy Drugs Sales Share by Country (2021-2032) Figure 71. Cancer Immunotherapy Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Cancer Immunotherapy Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GSK
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Hengrui Medicine
  • Gilead Sciences
  • Exelixis
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Immunotherapy Drugs Market by Type
  3. 1.2.1 Global Cancer Immunotherapy Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CAR-T Cell Therapy
  5. 1.2.3 Cytokine-Based Immunotherapy
  6. 1.2.4 Immune Checkpoint Inhibitors
  7. 1.2.5 Other
  8. 1.3 Cancer Immunotherapy Drugs Market by Application
  9. 1.3.1 Global Cancer Immunotherapy Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Blood-related Cancer
  11. 1.3.3 Breast Cancer
  12. 1.3.4 Prostate Cancer
  13. 1.3.5 Lung Cancer
  14. 1.3.6 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Cancer Immunotherapy Drugs Market Dynamics
  1. 2.1 Cancer Immunotherapy Drugs Industry Trends
  2. 2.2 Cancer Immunotherapy Drugs Industry Drivers
  3. 2.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cancer Immunotherapy Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cancer Immunotherapy Drugs Revenue by Region
  3. 3.2.1 Global Cancer Immunotherapy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cancer Immunotherapy Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cancer Immunotherapy Drugs Sales by Region
  9. 3.4.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cancer Immunotherapy Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Cancer Immunotherapy Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cancer Immunotherapy Drugs Revenue by Manufacturers
  2. 4.1.1 Global Cancer Immunotherapy Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cancer Immunotherapy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Immunotherapy Drugs Sales by Manufacturers
  6. 4.2.1 Global Cancer Immunotherapy Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cancer Immunotherapy Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cancer Immunotherapy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cancer Immunotherapy Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cancer Immunotherapy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cancer Immunotherapy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cancer Immunotherapy Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Cancer Immunotherapy Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cancer Immunotherapy Drugs Market CR5 and HHI
  16. 4.8.2 2025 Cancer Immunotherapy Drugs Tier 1, Tier 2, and Tier 3
5 Cancer Immunotherapy Drugs Market by Type
  1. 5.1 Global Cancer Immunotherapy Drugs Revenue by Type
  2. 5.1.1 Global Cancer Immunotherapy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cancer Immunotherapy Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cancer Immunotherapy Drugs Sales by Type
  6. 5.2.1 Global Cancer Immunotherapy Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cancer Immunotherapy Drugs Price by Type
6 Cancer Immunotherapy Drugs Market by Application
  1. 6.1 Global Cancer Immunotherapy Drugs Revenue by Application
  2. 6.1.1 Global Cancer Immunotherapy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cancer Immunotherapy Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cancer Immunotherapy Drugs Sales by Application
  6. 6.2.1 Global Cancer Immunotherapy Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cancer Immunotherapy Drugs Price by Application
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck KGaA
  20. 7.4.1 Merck KGaA Company Information
  21. 7.4.2 Merck KGaA Business Overview
  22. 7.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
  24. 7.4.5 Merck KGaA Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 Seagen
  68. 7.12.1 Seagen Company Information
  69. 7.12.2 Seagen Business Overview
  70. 7.12.3 Seagen Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
  72. 7.12.5 Seagen Recent Developments
  73. 7.13 Regeneron
  74. 7.13.1 Regeneron Company Information
  75. 7.13.2 Regeneron Business Overview
  76. 7.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
  78. 7.13.5 Regeneron Recent Developments
  79. 7.14 Ono Pharmaceutical
  80. 7.14.1 Ono Pharmaceutical Company Information
  81. 7.14.2 Ono Pharmaceutical Business Overview
  82. 7.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
  84. 7.14.5 Ono Pharmaceutical Recent Developments
  85. 7.15 Merck & Co
  86. 7.15.1 Merck & Co Company Information
  87. 7.15.2 Merck & Co Business Overview
  88. 7.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
  90. 7.15.5 Merck & Co Recent Developments
  91. 7.16 Innovent
  92. 7.16.1 Innovent Company Information
  93. 7.16.2 Innovent Business Overview
  94. 7.16.3 Innovent Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
  96. 7.16.5 Innovent Recent Developments
  97. 7.17 Hengrui Medicine
  98. 7.17.1 Hengrui Medicine Company Information
  99. 7.17.2 Hengrui Medicine Business Overview
  100. 7.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
  102. 7.17.5 Hengrui Medicine Recent Developments
  103. 7.18 Gilead Sciences
  104. 7.18.1 Gilead Sciences Company Information
  105. 7.18.2 Gilead Sciences Business Overview
  106. 7.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
  108. 7.18.5 Gilead Sciences Recent Developments
  109. 7.19 Exelixis
  110. 7.19.1 Exelixis Company Information
  111. 7.19.2 Exelixis Business Overview
  112. 7.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
  114. 7.19.5 Exelixis Recent Developments
  115. 7.20 Bristol-Myers Squibb
  116. 7.20.1 Bristol-Myers Squibb Company Information
  117. 7.20.2 Bristol-Myers Squibb Business Overview
  118. 7.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
  120. 7.20.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Cancer Immunotherapy Drugs Market Size by Type
  2. 8.1.1 North America Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Cancer Immunotherapy Drugs Price by Type (2021-2032)
  5. 8.2 North America Cancer Immunotherapy Drugs Market Size by Application
  6. 8.2.1 North America Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Cancer Immunotherapy Drugs Price by Application (2021-2032)
  9. 8.3 North America Cancer Immunotherapy Drugs Market Size by Country
  10. 8.3.1 North America Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cancer Immunotherapy Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Cancer Immunotherapy Drugs Market Size by Type
  2. 9.1.1 Europe Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Cancer Immunotherapy Drugs Price by Type (2021-2032)
  5. 9.2 Europe Cancer Immunotherapy Drugs Market Size by Application
  6. 9.2.1 Europe Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Cancer Immunotherapy Drugs Price by Application (2021-2032)
  9. 9.3 Europe Cancer Immunotherapy Drugs Market Size by Country
  10. 9.3.1 Europe Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cancer Immunotherapy Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Cancer Immunotherapy Drugs Market Size by Type
  2. 10.1.1 China Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Cancer Immunotherapy Drugs Price by Type (2021-2032)
  5. 10.2 China Cancer Immunotherapy Drugs Market Size by Application
  6. 10.2.1 China Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Cancer Immunotherapy Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Immunotherapy Drugs Market Size by Type
  2. 11.1.1 Asia Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Cancer Immunotherapy Drugs Price by Type (2021-2032)
  5. 11.2 Asia Cancer Immunotherapy Drugs Market Size by Application
  6. 11.2.1 Asia Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Cancer Immunotherapy Drugs Price by Application (2021-2032)
  9. 11.3 Asia Cancer Immunotherapy Drugs Market Size by Country
  10. 11.3.1 Asia Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cancer Immunotherapy Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Immunotherapy Drugs Market Size by Type
  2. 12.1.1 SAMEA Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cancer Immunotherapy Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Cancer Immunotherapy Drugs Market Size by Application
  6. 12.2.1 SAMEA Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cancer Immunotherapy Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Cancer Immunotherapy Drugs Market Size by Country
  10. 12.3.1 SAMEA Cancer Immunotherapy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cancer Immunotherapy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cancer Immunotherapy Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cancer Immunotherapy Drugs Value Chain Analysis
  2. 13.1.1 Cancer Immunotherapy Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cancer Immunotherapy Drugs Production Mode & Process
  6. 13.2 Cancer Immunotherapy Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cancer Immunotherapy Drugs Distributors
  9. 13.2.3 Cancer Immunotherapy Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst